Beacon Pharmaceuticals Income Statement

Financials in millions BDT. Fiscal year is July - June.

Millions BDT. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	Jun '20 Jun 30, 2020
Revenue	11,579	10,702	8,510	8,023	7,121	5,591
Revenue Growth (YoY)	23.15%	25.75%	6.07%	12.66%	27.37%	20.31%
Cost of Revenue	5,609	5,215	4,251	3,906	3,452	2,724
Gross Profit	5,970	5,487	4,259	4,116	3,669	2,867
Selling, General & Admin	3,793	3,672	3,295	2,499	2,307	2,533
Other Operating Expenses	-13.85	-13.85	-14.86	-	-	-
Operating Expenses	3,779	3,659	3,280	2,499	2,307	2,533
Operating Income	2,191	1,828	979.12	1,617	1,362	333.47
Interest Expense	-1,284	-1,003	-460.92	-337.96	-164.82	-149.33
Interest & Investment Income	227.86	227.86	155.13	0.32	3.24	1.31
Currency Exchange Gain (Loss)	-93.69	-93.69	2.68	0.5	-	-
Other Non Operating Income (Expenses)	59.94	-	-	9.81	-1.98	-0.95
EBT Excluding Unusual Items	1,102	959.82	676.01	1,290	1,198	184.5
Gain (Loss) on Sale of Assets	-6.5	-6.5	3.07	3.04	-	-
Pretax Income	1,095	953.32	679.07	1,293	1,198	184.5
Income Tax Expense	524.99	432.31	169.23	357.93	334.99	-196.19
Net Income	570.05	521.01	509.84	935.04	863.17	380.69
Net Income to Common	570.05	521.01	509.84	935.04	863.17	380.69
Net Income Growth	-13.90%	2.19%	-45.47%	8.33%	126.74%	223.44%
Shares Outstanding (Basic)	231	231	231	231	231	231
Shares Outstanding (Diluted)	231	231	231	231	231	231
EPS (Basic)	2.47	2.26	2.21	4.05	3.74	1.65
EPS (Diluted)	2.47	2.26	2.21	4.05	3.74	1.65
EPS Growth	-13.90%	2.19%	-45.47%	8.33%	126.74%	223.44%
Free Cash Flow	1,516	-1,275	-1,193	-637.07	-116.85	-22.8
Free Cash Flow Per Share	6.56	-5.52	-5.17	-2.76	-0.51	-0.10
Dividend Per Share	2.000	2.000	1.600	1.600	1.500	-
Dividend Growth	25.00%	25.00%	-	6.67%	-	-
Gross Margin	51.56%	51.27%	50.05%	51.31%	51.52%	51.28%
Operating Margin	18.92%	17.09%	11.51%	20.16%	19.12%	5.96%
Profit Margin	4.92%	4.87%	5.99%	11.65%	12.12%	6.81%
Free Cash Flow Margin	13.09%	-11.91%	-14.02%	-7.94%	-1.64%	-0.41%
EBITDA	2,723	2,356	1,498	2,057	1,747	844.48
EBITDA Margin	23.52%	22.02%	17.60%	25.64%	24.53%	15.10%
D&A For EBITDA	532.21	527.78	518.92	439.7	385.16	511.01
EBIT	2,191	1,828	979.12	1,617	1,362	333.47
EBIT Margin	18.92%	17.09%	11.51%	20.16%	19.12%	5.96%
Effective Tax Rate	47.94%	45.35%	24.92%	27.68%	27.96%	-
Advertising Expenses	-	72.55	69.04	68.5	52.97	1,004

Updated Feb 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.